ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
UCB (PK)

UCB (PK) (UCBJY)

89.42
0.45
(0.51%)
Closed September 19 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
89.42
Bid
87.45
Ask
90.02
Volume
2,609
88.73 Day's Range 89.44
34.85 52 Week Range 91.89
Market Cap
Previous Close
88.97
Open
88.74
Last Trade Time
Financial Volume
$ 232,225
VWAP
89.0092
Average Volume (3m)
13,674
Shares Outstanding
379,189,796
Dividend Yield
1.03%
PE Ratio
176.93
Earnings Per Share (EPS)
0.9
Revenue
4.87B
Net Profit
343M

About UCB (PK)

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector
Pharmaceutical Preparations
Industry
Chemicals & Allied Products
Website
Headquarters
Brussels, Brussels-capital Region, Bel
Founded
1928
UCB (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker UCBJY. The last closing price for UCB (PK) was $88.97. Over the last year, UCB (PK) shares have traded in a share price range of $ 34.85 to $ 91.89.

UCB (PK) currently has 379,189,796 shares outstanding. The market capitalization of UCB (PK) is $33.74 billion. UCB (PK) has a price to earnings ratio (PE ratio) of 176.93.

UCBJY Latest News

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance transformation as leading examples of innovation in...

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis show use of newer anti-epilepsy drugs, access to...

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company...

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest step towards UCB goal of extending treatment...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR Newswire ATLANTA, Dec. 8, 2014 ATLANTA, Dec. 8, 2014...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy -- Primary efficacy and safety...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care - Atlanta-based Collaboration Will Explore the Potential of Big Data to Help Inform...

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES) - 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) - First...

UCB shows strong scientific presence at leading rheumatology meeting

UCB shows strong scientific presence at leading rheumatology meeting -- Data to be presented at the ACR/ARHP Annual Meeting on UCB's marketed product CIMZIA® (certolizumab pegol) and the...

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB PR Newswire BOSTON and NEW YORK, Nov. 7, 2014 BOSTON and NEW YORK, Nov. 7, 2014 /PRNewswire/...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.090.10075002798689.3391.8987.916722689.66666185DR
4-0.18-0.20089285714389.691.8987.916485689.83564794DR
1215.5821.099674972973.8491.8973.5151367482.15309429DR
2631.012553.09677695558.407591.8958.2821928772.26453645DR
5245.735104.69268627743.68591.8934.851706459.4925591DR
15634.964.013206162954.5291.8932.822092748.06812106DR
26054.32154.75783475835.191.8932.451967250.08402654DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JUVAFJuva Life Inc (CE)
$ 0.002
(199,900.00%)
15.5k
BLSTFBlackstone Minerals Ltd (PK)
$ 0.0271
(27,000.00%)
30k
TLSSTransportation and Logistics Systems Inc (CE)
$ 0.0001
(9,900.00%)
3.1M
GOSYGeckosystems International Corp (CE)
$ 0.0001
(9,900.00%)
1.15M
MMEXMMEX Resources Corporation (PK)
$ 0.0001
(9,900.00%)
745.41k
TEVNFTevano Systems Holdings Inc (CE)
$ 0.000001
(-99.99%)
10k
SNSTSunset Capital Assets Omc (CE)
$ 0.000001
(-99.99%)
85.03k
PNDDFPender Growth Fund Inc (PK)
$ 0.0012
(-99.98%)
100
HLLPFHello Pal International Inc (CE)
$ 0.000001
(-99.90%)
5k
ELOXEloxx Pharmaceuticals Inc (CE)
$ 0.000001
(-99.83%)
297
IMTLImage Protect Inc (PK)
$ 0.0002
(100.00%)
591.38M
TMGIMarquie Group Inc (PK)
$ 0.0001
(0.00%)
244.01M
SINCSincerity Applied Materials Holdings Corporation (PK)
$ 0.001
(42.86%)
214.48M
SIRCSolar Integrated Roofing Corporation (PK)
$ 0.0002
(0.00%)
167.08M
HMBLHUMBL Inc (PK)
$ 0.0001
(-33.33%)
118.85M

Discussion

View Full Feed
linkvest linkvest 4 minutes ago
If they get filled it will be fast as it should run up some even though its a Friday... To many great things are happening with IGPK right now so with just anticipations for the week end, it should still move up. Love to see it over that MMs dreaded penny mark.
IGPK
A51Rob A51Rob 5 minutes ago
Has anyone found out any info on this suppose it new CEO Alfredo Papadakis
VGTL
t1215s t1215s 5 minutes ago
Jhd Nahhhhhh ,maybe he’s just seasick 😉😂

GLTA-Ts
COOP
madras50 madras50 5 minutes ago
That shows the character of Whale, caught up in the # of followers.
Level2Me Level2Me 5 minutes ago
How about after today? What is better than best?
PYPL
dbergh dbergh 6 minutes ago
I did some looking into why Venezuela collapsed and what you posted was is the nail in the coffin the Media got in bed with the government

They are taking the blue print of what happened to Venezuela turn the people against the government put in a lot of government social programs
FlyingDutchman FlyingDutchman 6 minutes ago
its all in the charts folks. set it up right/back egineer it peace
Yo-Yo Yo-Yo 6 minutes ago
You cool as all get out v!!! And got a lot of knowledge!!!
The Night Stalker The Night Stalker 6 minutes ago
churn
BCDS
Whalatane Whalatane 6 minutes ago
North. Apologies on my quick scan . Yes Naz Co's often get longer than the initial 180 days to regain compliance ...and we are near that 180 day pt now .
Don't know of any that have been given more than a year tho.
Kiwi
AMRN
ipo_dude ipo_dude 6 minutes ago
Lol
GSIW
Axeman Axeman 7 minutes ago
Probably back to 6x7 in the morning
SINC
Vexari Vexari 7 minutes ago
Yet another perspective

old.bitchute.com/video/AkgxkEFBwZu6/ To be entertained
gfp927z gfp927z 8 minutes ago
>>> John Paulson Warns Of Equity Market Exit > Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit


Benzinga

by Shanthi Rexaline

S
OMOLIVES OMOLIVES 8 minutes ago
Nope. He started abusing the system in August of 2012. His latest was August of 2024. His game started:

https://investorshub.advfn.com/uimage/uploads/2024/9/19/lupjxCapture.PNG

Then was somehow able to wait five full years and start filing insane financials and relen
The GidDy uP Kid The GidDy uP Kid 8 minutes ago
.1369 NLSP... insiders own a good 36%, Daily psar kissing to fliP to the Upside, on the doJi...
https://schrts.co/rXTZqrSw
NLSP
StockInfo11 StockInfo11 8 minutes ago
As highlighted in a recent video update, Luca Mining (LUCA.v LUCMF) had a strong 2nd quarter, with revenue and net earnings increasing 49% & 217% YoY respectively.
https://youtu.be/zV0QCUTNlAo
In the same time period, Gold Eq production expanded at both LUCA's Campo Morado and Tahuehu
LUCMF
gfp927z gfp927z 9 minutes ago
>>> John Paulson Warns Of Equity Market Exit > Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit


Benzinga

by Shanthi Rexaline

S
kaylex13 kaylex13 9 minutes ago
Didn’t get as much as i wanted today GTC bids in place
BNCM
SkyLimit2022 SkyLimit2022 9 minutes ago
NotSure2,

4 or 5?? Really? 😶

At first glance, I would put DCVax-L at a priority 2 maybe (high benefit, medium cost), especially for GBM.

There’s also a reasonable case to be made for DCVax-L to be categorized as priority 1 considering rGBM or ev
NWBO
ErnieBilco ErnieBilco 9 minutes ago
Kiwi, I upped it to .32 just so you know, I of course would be buying Huuuuuge at .20 but seems to be a dream at this point.

Thanks for checking
UNCY
The GidDy uP Kid The GidDy uP Kid 9 minutes ago
...
HRAL

Your Recent History

Delayed Upgrade Clock